Ireland
--:--IST
Priya Life Science Clinical trial register
Trackers› Clinical trials› Follicular Lymphoma (FL)
Clinical trial register · Poland

Follicular Lymphoma (FL) Trials in Poland, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Poland and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2721 matching records held by the registry are in this view. Synced 19 Nov 2026, 03:18 UTC
2721
Studies in scope
all four open statuses
1385
Recruiting now
open to new participants
507
Lead sponsors
across recruiting studies
Top sites
Krakow 7 Lodz 5 Lublin 4 Warsaw 4 Gdansk 3
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Follicular Lymphoma (FL) trials in Poland

8 of 2721 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Poland
Start
Recruiting
Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
NCT06980116Relapsed or Refractory B-cell Malignancies, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Follicular Lymphoma (FL), Marginal Zone Lymphoma (MZL)
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Phase 1
85
Krakow, Lodz, Lublin, Skórzewo
2025-03-31
Active, closed
Regeneron Pharmaceuticals
Phase 3
733
Krakow, Skorzewo, Bydgoszcz, Gdansk, Katowice, Lodz, Lublin, Warsaw
2023-11-14
Active, closed
Novartis Pharmaceuticals
Phase 3
109
Poznan, Gliwice, Gdansk, Lodz
2023-10-02
Recruiting
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
NCT05131022Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL)
Nurix Therapeutics, Inc.
Phase 1
572
Skórzewo, Krakow, Wroclaw, Warsaw, Katowice, Lublin
2022-04-13
Recruiting
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
NCT03460977Metastatic Castration Resistant Prostate Cancer (mCRPC), Small Cell Lung Cancer (SCLC), Follicular Lymphoma (FL)
Pfizer
Phase 1
453
Bydgoszcz, Koszalin, Krakow, Rzeszów, Warsaw
2018-04-17
Rows per page Showing 1–8 of 8
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Polish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 21 November 2026. https://priyalifescience.com/clinical-trials-poland/condition/follicular-lymphoma-fl

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Poland and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,721 studies in total at the last sync on 19 Nov 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 8 of those studies listing the condition Follicular Lymphoma (FL).

How many Follicular Lymphoma (FL) trials are recruiting in Poland?

4 of the 8 studies on this page are recruiting new participants as of the 19 Nov 2026, 03:18 UTC sync. A further 0 have not yet opened recruitment, 4 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Follicular Lymphoma (FL)), 8 studies
PhaseStudiesRecruitingShare
Phase 35162.5%
Phase 13337.5%

Most active sponsors

Lead sponsors with the most studies (Follicular Lymphoma (FL))
Lead sponsorStudiesRecruiting
Genmab20
Regeneron Pharmaceuticals21
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.11
Novartis Pharmaceuticals10
Nurix Therapeutics, Inc.11
Pfizer11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.